| Title | Presenter/Author | Location | Track | Day | Time | Abstract | Type | Board |
| A phase 2 trial of ABVD followed by brentuximab vedotin consolidation in limited stage non-bulky Hodgkin lymphoma | Steven I. Park, MD (University of North Carolina Lineberger Comprehensive Cancer Center) | E354b | Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia | Sunday | 12:09 – 12:21 | 7508 | Oral Abstract Session | |
| Checkmate 205: Nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV)—A phase 2 study. | Anas Younes, MD (Memorial Sloan Kettering Cancer Center) | Hall A | Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia | Monday | 8:00 – 11:30 | 7535 | Poster Session | #91 |
| Checkmate 205: Nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV)—A phase 2 study. | Anas Younes, MD (Memorial Sloan Kettering Cancer Center) | E354b | Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia | Monday | 1:15 – 2:45 | 7535 | Poster Discussion Session | |
| A phase 1/2 study to evaluate safety and efficacy of nivolumab plus brentuximab vedotin in patients with CD30-expressing relapsed/refractory non-Hodgkin lymphomas (NHLs). | Philippe Armand, MD, PhD (Dana-Farber Cancer Institute) | Hall A | Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia | Monday | 8:00 – 11:30 | TPS7576 | Poster Session | #130a |
| Metabolic tumor volume to predict event-free survival in patients with relapsed/refractory HL treated with brentuximab vedotin-based salvage therapy. | Somali C. Gavane, MBBS (Memorial Sloan Kettering Cancer Center) | Hall A | Tumor Biology | Monday | 1:00 – 4:30 | 11566 | Poster Session | #263 |
| | | | | | | | |
| Ado-trastuzumab emtansine | | | | | | | | |
| Title | Presenter/Author | Location | Track | Day | Time | Abstract | Type | Board |
| Patient-reported outcomes (PROs) from MARIANNE: A phase III study of trastuzumab emtansine (T-DM1) +/- pertuzumab (P) vs trastuzumab + taxane (HT) for HER2-positive advanced breast cancer. | Carlos H. Barrios (PUCRS School of Medicine) | Hall A | Breast Cancer—HER2/ER | Sunday | 8:00 – 11:30 | 593 | Poster Session | #81 |
| Response to ado-trastuzumab emtansine according to RANO criteria in central nervous system metastases of HER2 positive breast cancers. | Audrey Mailliez, MD (Centre Oscar Lambret) | Hall A | Breast Cancer—HER2/ER | Sunday | 8:00 – 11:30 | 605 | Poster Session | #93 |
| Role of tumor infiltrating lymphocytes (TILs) in HER2+ metastatic breast cancers (MBC) treated with trastuzumab emtansine (T-DM1) or lapatinib plus capecitabine (L+C) (EMILIA Trial). | Sunil S. Badve, MD (Indiana University) | Hall A | Breast Cancer—HER2/ER | Sunday | 8:00 – 11:30 | 607 | Poster Session | #95 |
| Academic and Community Cancer Research United (ACCRU) RU011301I: Adjuvant ado-trastuzumab emtansine (T-DM1) for older patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer. | Rachel A. Freedman, MD, MPH (Dana-Farber Cancer Institute) | Hall A | Breast Cancer—HER2/ER | Sunday | 8:00 – 11:30 | TPS629 | Poster Session | #109a |
| HERMIONE: A Phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician’s choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and ado-trastuzumab emtansine (T-DM1). | Kathy Miller, MD (Indiana University Melvin and Bren Simon Cancer Center | Hall A | Breast Cancer—HER2/ER | Sunday | 8:00 – 11:30 | TPS631 | Poster Session | #110a |
| Pathologic complete response (pCR) rates after neoadjuvant trastuzumab emtansine (T-DM1 [K]) + pertuzumab (P) vs docetaxel + carboplatin + trastuzumab + P (TCHP) treatment in patients with HER2-positive (HER2+) early breast cancer (EBC) (KRISTINE). | Sara A. Hurvitz (David Geffen School of Medicine, University of California Los Angeles | Hall D1 | Breast Cancer—HER2/ER | Monday | 1:15 – 1:27 | 500 | Oral Abstract Session | |
| | | | | | | | |
| Sacituzumab Govitecan (IMMU-132) | | | | | | | | |
| Title | Presenter/Author | Location | Track | Day | Time | Abstract | Type | Board |
| Therapy of relapsed/refractory metastatic triple-negative breast cancer (mTNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase II results. | Aditya Bardia, MD, MPH (Massachusetts General Hospital Cancer Center) | Hall D1 | Breast Cancer—Triple-Negative/Cytotoxics/Local Therapy, Breast Cancer—HER2/ER | Friday | 4:30 – 4:42 | LBA509 | Clinical Science Symposium | |
| Trop-2 as a therapeutic target for the antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132), in patients (pts) with previously treated metastatic small-cell lung cancer (mSCLC). | Alexander Starodub, MD, PhD (Indiana University Health Goshen Center for Cancer Care) | Hall A | Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers | Saturday | 8:00 – 11:30 | 8559 | Poster Session | #187 |
| Therapy of metastatic, non-small cell lung cancer (mNSCLC) with the anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132). | D. Ross Camidge, MD, PhD (University of Colorado) | Hall B1 | Lung Cancer—Non-Small Cell Metastatic | Monday | 2:03 – 2:15 | 9011 | Clinical Science Symposium | |
| | | | | | | | |
| Enfortumab vedotin | | | | | | | | |
| Title | Presenter/Author | Location | Track | Day | Time | Abstract | Type | Board |
| Anti-tumor activity, safety and pharmacokinetics (PK) of ASG-22CE (ASG-22ME; enfortumab vedotin) in a phase I dose escalation trial in patients (Pts) with metastatic urothelial cancer (mUC). | Jonathan E. Rosenberg, MD (Memorial Sloan Kettering Cancer Center) | Hall A | Genitourinary (Nonprostate) Cancer | Monday | 1:00 – 4:30 | 4533 | Poster Session | #156 |
| | | | | | | | |
| Lifastuzumab vedotin | | | | | | | | |
| Title | Presenter/Author | Location | Track | Day | Time | Abstract | Type | Board |
| A Randomized, Open-Label, Phase 2 Study of Anti-NaPi2b Antibody-Drug Conjugate (ADC) Lifastuzumab (Lifa) Vedotin (DNIB0600A) Compared to Pegylated Liposomal Doxorubicin (PLD) in Patients (Pts) with Platinum-Resistant Ovarian Cancer (PROC). | Susana N. Banerjee, MBBS, MA, PhD, MRCP (Royal Marsden Hospital) | Hall A | Gynecologic Cancer | Monday | 1:00 – 4:30 | 5569 | Poster Session | #392 |
| | | | | | | | |
| Rovalpituzumab tesirine | | | | | | | | |
| Title | Presenter/Author | Location | Track | Day | Time | Abstract | Type | Board |
| Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC). | Charles M. Rudin, MD, PhD (Memorial Sloan Kettering Cancer Center) | Arie Crown Theater | Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers | Sunday | 9:44 – 9:56 | LBA8505 | Oral Abstract Session | |
| Metastatic melanoma, glioblastoma and high-grade extrapulmonary neuroendocrine carcinomas (NECs) as novel indications for rovalpituzumab tesirine: A delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC). | Stanford L. Peng, MD, PhD (Stemcentrx, Inc.) | Hall A | Tumor Biology | Monday | 1:00 – 4:30 | 11611 | Poster Session | #308 |
| | | | | | | | |
| PSMA ADC | | | | | | | | |
| Title | Presenter/Author | Location | Track | Day | Time | Abstract | Type | Board |
| PSMA ADC for progressive glioblastoma: Phase II Brown University Oncology Research Group Study. | Heinrich Elinzano, MD (Rhode Island Hospital) | Hall A | Central Nervous System Tumors | Saturday | 1:00 – 4:30 | 2065 | Poster Session | #252 |
| | | | | | | | |
| EC1169 | | | | | | | | |
| Title | Presenter/Author | Location | Track | Day | Time | Abstract | Type | Board |
| Phase 1 study of the PSMA-targeted tubulysin small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC). | Michael J. Morris, MD (Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College) | Hall A | Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics | Sunday | 8:00 – 11:30 | 2586 | Poster Session | #286 |
| | | | | | | | |
| ABBV-399 | | | | | | | | |
| Title | Presenter/Author | Location | Track | Day | Time | Abstract | Type | Board |
| Phase 1, open-label, dose-escalation and expansion study of ABBV-399, an antibody drug conjugate (ADC) targeting c-Met, in patients (pts) with advanced solid tumors. | John H. Strickler, MD (Duke University Medical Center) | Hall A | Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics | Sunday | 8:00 – 11:30 | 2510 | Poster Session | #210 |
| Phase 1, open-label, dose-escalation and expansion study of ABBV-399, an antibody drug conjugate (ADC) targeting c-Met, in patients (pts) with advanced solid tumors. | John H. Strickler, MD (Duke University Medical Center) | Arie Crown Theater | Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics | Sunday | 11:30 – 12:45 | 2510 | Poster Discussion Session | |
| | | | | | | | |
| SAR566658 | | | | | | | | |
| Title | Presenter/Author | Location | Track | Day | Time | Abstract | Type | Board |
| A phase I study of SAR566658, an anti CA6-antibody drug conjugate (ADC), in patients (Pts) with CA6-positive advanced solid tumors (STs)(NCT01156870). | Carlos Alberto Gomez-Roca, MD (Institut Universitaire du Cancer de Toulouse) | Hall A | Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics | Sunday | 8:00 – 11:30 | 2511 | Poster Session | #211 |
| A phase I study of SAR566658, an anti CA6-antibody drug conjugate (ADC), in patients (Pts) with CA6-positive advanced solid tumors (STs)(NCT01156870). | Carlos Alberto Gomez-Roca, MD (Institut Universitaire du Cancer de Toulouse) | Arie Crown Theater | Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics | Sunday | 11:30 – 12:45 | 2511 | Poster Discussion Session | |
| | | | | | | | |
| ABT-414 | | | | | | | | |
| Title | Presenter/Author | Location | Track | Day | Time | Abstract | Type | Board |
| Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, as monotherapy in epidermal growth factor receptor (EGFR) amplified, recurrent glioblastoma (GBM). | Martin J. Van Den Bent, MD (Erasmus MC Cancer Center) | Hall A | Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics | Sunday | 8:00 – 11:30 | 2542 | Poster Session | #242 |
| | | | | | | | |
| Inotuzumab ozogamicin | | | | | | | | |
| Title | Presenter/Author | Location | Track | Day | Time | Abstract | Type | Board |
| Patient-reported outcomes (PRO) from a global phase 3 randomized controlled trial (RCT) of inotuzumab ozogamicin (InO) vs standard care (SC) for relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL). | Hagop M Kantarjian, MD (The University of Texas MD Anderson Cancer Center, Department of Leukemia) | Hall A | Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant | Monday | 8:00 – 11:30 | 7027 | Poster Session | #19 |
| Inotuzumab ozogamicin (InO) for relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) in the phase III INO-VATE trial: Efficacy and safety by prior therapy. | Daniel J. DeAngelo, MD, PhD (Dana-Farber Cancer Institute) | Hall A | Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant | Monday | 8:00 – 11:30 | 7028 | Poster Session | #20 |
| Efficacy and safety of inotuzumab ozogamicin (InO) in older patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) enrolled in the phase 3 INO-VATE trial | Elias Jabbour, MD (The University of Texas MD Anderson Cancer Center) | Hall A | Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant | Monday | 8:00 – 11:30 | 7029 | Poster Session | #21 |
| | | | | | | | |
| Anetumab ravtansine | | | | | | | | |
| Title | Presenter/Author | Location | Track | Day | Time | Abstract | Type | Board |
| A pivotal randomized phase II study of anetumab ravtansine or vinorelbine in patients with advanced or metastatic pleural mesothelioma after progression on platinum/pemetrexed-based chemotherapy (NCT02610140). | Raffit Hassan, MD (Thoracic and Gastrointestinal Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health | Hall A | Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers | Saturday | 8:00 – 11:30 | TPS8576 | Poster Session | #201a |
| Phase I study of anti-mesothelin antibody drug conjugate anetumab ravtansine (AR). | George R. Blumenschein, MD (Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center) | Hall A | Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics | Sunday | 8:00 – 11:30 | 2509 | Poster Session | #209 |
| Phase I study of anti-mesothelin antibody drug conjugate anetumab ravtansine (AR). | George R. Blumenschein, MD (Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center) | Arie Crown Theater | Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics | Sunday | 11:30 – 12:45 | 2509 | Poster Discussion Session | |
| | | | | | | | |
| Mirvetuximab soravtansine | | | | | | | | |
| Title | Presenter/Author | Location | Track | Day | Time | Abstract | Type | Board |
| IMGN853 (mirvetuximab soravtansine), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC): single agent activity in platinum-resistant epithelial ovarian cancer (EOC) patients (pts). | Kathleen N. Moore, MD (University of Oklahoma Health Sciences Center) | Hall A | Gynecologic Cancer | Monday | 1:00 – 4:30 | 5567 | Poster Session | #390 |
| FORWARD II: A Phase 1b study to evaluate the safety, tolerability and pharmacokinetics of mirvetuximab soravtansine (IMGN853) in combination with bevacizumab, carboplatin or pegylated liposomal doxorubicin in adults with folate receptor alpha (FRα)-positive advanced epithelial ovarian cancer (EOC), primary peritoneal, fallopian tube, or endometrial cancer. | David M. O’Malley, MD (The Ohio State University College of Medicine) | Hall A | Gynecologic Cancer | Monday | 1:00 – 4:30 | TPS5611 | Poster Session | #427a |
